ClinicalTrials.gg
CompletedNCT04669600Updated Sep 10, 2025Results posted

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

A Phase 2 interventional study of SAR445088 (BIVV020) in Immune Thrombocytopenia (ITP), sponsored by Bioverativ, a Sanofi company. Completed at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Bioverativ, a Sanofi company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain — 14 open to participants now, 18 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Spain.

Enrollment
43rd of 44
12 · median 69
Started
2021
with 2 others
Phase 2
11 of 50
1 open now
Registered
25th of 50
by date

Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain, this one is the 43rd largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2021, is one of 11 in phase 2, and was the 25th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

14 of the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain, or all of them as a file.
02

Study summary

Primary Objective:

- To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP)

Secondary Objectives:

  • To assess the safety and tolerability of BIVV020
  • To assess the pharmacokinetics of BIVV020
  • To assess the response rate of treatment with BIVV020
  • To assess the time to response
  • To assess the effect of treatment with BIVV020 on the requirement for rescue ITP therapy
  • To assess the immunogenicity of BIVV020
Read the detailed description

Study duration:

  • Screening period: up to 56 days
  • Transition period between last sutimlimab dose and first dose of BIVV020 (for participants who were previously receiving sutimlimab): 14 days, included as part of the 56-day Screening period. Treatment duration: Minimum 52 weeks.

Visit frequency:

  • Day 1
  • Day 4
  • Weeks 1 to 6: Weekly
  • Weeks 7 to 12: Every other week
  • Weeks 13 to 24: Every 4 weeks
  • Weeks 25+: At least every 8 weeks
  • End of Study visit: 22 weeks after the last dose of BIVV020
03

Conditions studied

  • Immune Thrombocytopenia (ITP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants ≥18 years of age at the time of signing the
  • Confirmed diagnosis of primary ITP; for participants who previously received sutimlimab in study TDR16218 (NCT03275454), a response to sutimlimab must have been obtained, as defined by count ≥30 × 10\^9/L on 2 visits at least 7 days apart
  • For participants who have not previously received sutimlimab: persistent/chronic ITP (ITP lasting for ≥6 months) and all the following conditions:

    1. Platelet count ≤30 × 10\^9/L on 2 occasions at least 5 days apart during the Screening Period;
    2. Lack of an adequate platelet count response (as defined by maintenance of sustained platelet count ≥30 × 109/L in the absence of bleeding) to at least 2 ITP treatments, 1 of which was a thrombopoietin receptor agonist. Other ITP treatments include: IVIg, anti-D immunoglobulin, , splenectomy, rituximab, cyclophosphamide, azathioprine, danazol, cyclosporin A, mycophenolate mofetil, or fostamatinib.
    3. If receiving weekly thrombopoietin receptor agonist dosing, the last dose must have been administered ≥7 days before the first dose of BIVV020. If receiving daily thrombopoietin receptor agonist dosing, the last dose must have been administered ≥24 hours before the first dose of BIVV020
    4. If applicable, concurrent administration of ITP medications (eg. corticosteroids, IVIg, azathioprine, danazol, cyclosporin A, mycophenolate mofetil, or thrombopoietin receptor agonists) is acceptable provided the participant has been on a stable dose for at least 1 month.
    5. If previously dosed with rituximab, the last dose of rituximab must have been administered at least 12 weeks before the first dose of BIVV020
  • Documented vaccinations against encapsulated bacterial pathogens (Neisseria meningitidis, including serogroup B where available, Haemophilus influenzae, and Streptococcus pneumoniae) within 5 years of enrollment
  • use for women of and men who were sexually active with a female partner of childbearing potential

Exclusion criteria

Exclusion criteria:

Participants were excluded from the study if any of the following criteria apply:

  • medical history or ongoing chronic illness that would jeopardize the safety of the participant or compromise the quality of the data derived from his/her participation in the study
  • Clinical diagnosis of SLE
  • Clinically relevant infection within the month prior to enrollment
  • History of venous or arterial thrombosis within the year prior to enrollment
  • Secondary ITP from any cause including lymphoma, chronic lymphocytic leukemia, and drug-induced thrombocytopenia
  • Positive surface antigen (HBsAg) or active infection
  • infection
  • Pregnant or lactating women
  • level \<10 g/dL

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    SAR445088

    Participants received SAR445088 (BIVV020).

    Drug: SAR445088 (BIVV020)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Durable Platelet Response

    A naive participant was a participant who did not use sutimlimab prior to enrollment. A switcher was a participant who used sutimlimab prior to enrollment. A naive participant was a responder if the platelet count was \>=50 × 10\^9/liter (L) at \>=50 percent (%) of scheduled visits, or for participants with baseline platelet count \<15 × 10\^9/L, a \>=20 × 10\^9/L increase in platelet count from baseline at \>=50% of scheduled visits, without receiving rescue immune thrombocytopenia (ITP) therapy. A switcher was a responder if the maintenance platelet count was \>=30 × 10\^9/L at \>=50% of scheduled visits, without receiving rescue ITP therapy.

    Time frame: From Week 3 to Week 24

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (SAE)

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed after the first study treatment administration in the safety analysis period which was defined as the period from the first study intervention administration to the end of study (EOS) visit (up to Week 103).

    Time frame: From first study treatment administration (Day 1) up to Week 103

  2. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology

    Criteria for potentially clinically significant laboratory abnormalities (PCSA): White blood cells: less than (\<)3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]), greater than or equal to (\>=)16.0 Giga/L; Lymphocytes: greater than (\>)4.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L); Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), \>=185 g/L (M) or \>=165 g/L (F), Decrease from baseline (DFB) \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets:\<100 Giga/L, \>=700 Giga/L. Only the worst case during the treatment-emergent (TE) period for each participant with worsening from baseline is presented.

    Time frame: On Days 1, 15, 29, at Weeks 8, 12, 24, and then every 8 weeks until the end of study (EOS) (Week 103)

  3. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Clinical Chemistry

    Criteria for PCSA: Blood Urea Nitrogen: \>=17 millimole (mmol)/L; Creatinine: \>=150 micromole (mcmol)/L (Adults), \>=30% and \<100% change from baseline, \>=100% change from baseline; Potassium: \<3 mmol/L, \>=5.5 mmol/L; Sodium: \<=129 mmol/L, \>=160 mmol/L; Aspartate Aminotransferase (AST): \>3 ULN, \>5 ULN, \>10 ULN, \>20 ULN; Alanine Aminotransferase (ALT): \>3 ULN, \>5 ULN, \>10 ULN, \>20 ULN; Alkaline Phosphatase (ALP): \>1.5 ULN; Bilirubin: \>1.5 ULN, \>2 ULN; ALT and Total Bilirubin: ALT \>3 ULN and TBILI \>2 ULN. Only the worst case during the TE period for each participant with worsening from baseline is presented.

    Time frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)

  4. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Coagulation

    The number of participants with PCSA for coagulation parameters during the TE period without PCSA definition by biological function are presented. The parameters evaluated were prothrombin time, prothrombin international normalized ratio and activated partial thromboplastin time (APTT).

    Time frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)

  5. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis

    Criteria for PCSA: potential of Hydrogen (pH) \<=4.6, \>=8. Only the worst case during the TE period for each participant with worsening from baseline is presented.

    Time frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)

  6. Plasma Concentrations of SAR445088 (BIVV020)

    Plasma samples were collected at specified timepoints.

    Time frame: 1-hour post-dose on Day 1, on Days 8, 15, 29, 43, at Weeks 12, 16, 24, 32, 40, 48, 56, 64, 72, 80 and EOS visit, up to 103 weeks

  7. Number of Responders to SAR445088 (BIVV020)

    A participant was a responder if the platelet count was \>=50 × 10\^9/L and there was a greater than 2-fold increase from baseline, measured on 2 occasions at least 7 days apart with the absence of bleeding \[bleeding score \>=2 on the World Health Organization (WHO) bleeding scale\] while the platelet counts were maintained above the threshold and lack of combination ITP therapy during this period. WHO bleeding scores: 1=Petechiae; 2=Mild blood loss; 3=Gross blood loss; and 4=Debilitating blood loss.

    Time frame: At Weeks 24 and 56

  8. Time to First Platelet Response

    Time to first platelet response was defined as greater than or equal to each of the following values: 50 × 10\^9/L or 100 × 10\^9/L (confirmed by 2 measurements at least 7 days apart). It was calculated as date of first occurrence of confirmed platelet count response before rescue therapy.

    Time frame: From Baseline (Day 1) up to Week 56

  9. Percentage of Participants Who Did Not Require Rescue Therapy for an Acute Episode of Thrombocytopenia After Week 3

    Data was collected to assess the effect of treatment with SAR445088 (BIVV020) on the requirement for rescue ITP therapy.

    Time frame: Up to Week 84

  10. Number of Participants With Anti-Drug Antibody (ADAs) Response to SAR445088 (BIVV020)

    Plasma samples were analyzed for the presence of ADAs for SAR445088 (BIVV020) using validated assays. Treatment-induced ADA was defined as ADAs that developed during the treatment-emergent period and without pre-existing ADA. Pre-existing ADA was defined as ADAs present in samples drawn before first study treatment administration. Treatment-boosted ADA positive was defined as pre-existing ADA (i.e., ADA positive at baseline) that was boosted at least a 9-fold increase of titer values during the treatment-emergent period than the baseline. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive during the treatment-emergent period. Inconclusive ADA was defined as the one that could not irrefutably be classified as with or without treatment-emergent ADA.

    Time frame: Up to Week 103

07

Results

Posted Feb 22, 2024

Participant flow

The study was conducted at 8 centers in 5 countries. A total of 20 participants were screened from 04 Feb 2021 to 07 Sep 2021, of which 8 were screen failures due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneSAR445088
Started12
Completed5
Not completed7
Withdrew: Withdrawal by subject1
Withdrew: Other6

Outcome measures

PrimaryPercentage of Participants With a Durable Platelet Response

A naive participant was a participant who did not use sutimlimab prior to enrollment. A switcher was a participant who used sutimlimab prior to enrollment. A naive participant was a responder if the platelet count was \>=50 × 10\^9/liter (L) at \>=50 percent (%) of scheduled visits, or for participants with baseline platelet count \<15 × 10\^9/L, a \>=20 × 10\^9/L increase in platelet count from baseline at \>=50% of scheduled visits, without receiving rescue immune thrombocytopenia (ITP) therapy. A switcher was a responder if the maintenance platelet count was \>=30 × 10\^9/L at \>=50% of scheduled visits, without receiving rescue ITP therapy.

Time frame:
From Week 3 to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Durable Platelet Response
percentage of participantsSAR445088
Naive participant0 (0.0 to 36.9)
Switcher25 (19.4 to 99.4)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (SAE)

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed after the first study treatment administration in the safety analysis period which was defined as the period from the first study intervention administration to the end of study (EOS) visit (up to Week 103).

Time frame:
From first study treatment administration (Day 1) up to Week 103
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (SAE)
ParticipantsSAR445088
Any TEAE8
Any Treatment Emergent SAE2
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology

Criteria for potentially clinically significant laboratory abnormalities (PCSA): White blood cells: less than (\<)3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]), greater than or equal to (\>=)16.0 Giga/L; Lymphocytes: greater than (\>)4.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L); Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), \>=185 g/L (M) or \>=165 g/L (F), Decrease from baseline (DFB) \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets:\<100 Giga/L, \>=700 Giga/L. Only the worst case during the treatment-emergent (TE) period for each participant with worsening from baseline is presented.

Time frame:
On Days 1, 15, 29, at Weeks 8, 12, 24, and then every 8 weeks until the end of study (EOS) (Week 103)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology
ParticipantsSAR445088
White blood cells: <3.0 Giga/L (NB) or <2.0 Giga/L (B)0
White blood cells: >=16.0 Giga/L3
Lymphocytes: >4.0 Giga/L2
Neutrophils: <1.5 Giga/L (NB) or <1.0 Giga/L (B)0
Monocytes: >0.7 Giga/L7
Basophils: >0.1 Giga/L3
Eosinophils: >0.5 Giga/L or >ULN (if ULN >=0.5 Giga/L)1
Hemoglobin: <=115 g/L (M) or <=95 g/L (F)0
Hemoglobin: >=185 g/L (M) or >=165 g/L (F)0
Hemoglobin: DFB >=20 g/L0
Hematocrit: <=0.37 v/v (M) or <=0.32 v/v (F)0
RBC: >=6 Tera/L0
Platelets: <100 Giga/L11
Platelets: >=700 Giga/L0
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Clinical Chemistry

Criteria for PCSA: Blood Urea Nitrogen: \>=17 millimole (mmol)/L; Creatinine: \>=150 micromole (mcmol)/L (Adults), \>=30% and \<100% change from baseline, \>=100% change from baseline; Potassium: \<3 mmol/L, \>=5.5 mmol/L; Sodium: \<=129 mmol/L, \>=160 mmol/L; Aspartate Aminotransferase (AST): \>3 ULN, \>5 ULN, \>10 ULN, \>20 ULN; Alanine Aminotransferase (ALT): \>3 ULN, \>5 ULN, \>10 ULN, \>20 ULN; Alkaline Phosphatase (ALP): \>1.5 ULN; Bilirubin: \>1.5 ULN, \>2 ULN; ALT and Total Bilirubin: ALT \>3 ULN and TBILI \>2 ULN. Only the worst case during the TE period for each participant with worsening from baseline is presented.

Time frame:
On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Clinical Chemistry
ParticipantsSAR445088
Blood Urea Nitrogen: >=17 mmol/L0
Creatinine: >=150 mcmol/L (Adults)1
Creatinine: >=30% and < 100% from baseline4
Creatinine:>=100% from baseline1
Potassium: <3 mmol/L0
Potassium: >=5.5 mmol/L1
Sodium:<=129 mmol/L0
Sodium: >=160 mmol/L0
AST: >3 ULN0
AST: >5 ULN0
AST: >10 ULN0
AST: >20 ULN0
ALT: >3 ULN0
ALT: >5 ULN0
ALT: >10 ULN0
ALT: >20 ULN0
ALP: > 1.5 ULN1
Bilirubin: >1.5 ULN0
Bilirubin: >2 ULN0
ALT and total bilirubin: ALT>3ULN and TBILI >2ULN0
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Coagulation

The number of participants with PCSA for coagulation parameters during the TE period without PCSA definition by biological function are presented. The parameters evaluated were prothrombin time, prothrombin international normalized ratio and activated partial thromboplastin time (APTT).

Time frame:
On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Coagulation
ParticipantsSAR445088
Prothrombin time: <Lower limit of normal (LLN)1
Prothrombin time: >ULN2
Prothrombin International Normalized Ratio: <LLN2
Prothrombin International Normalized Ratio: >ULN2
APTT: <LLN1
APTT: >ULN3
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis

Criteria for PCSA: potential of Hydrogen (pH) \<=4.6, \>=8. Only the worst case during the TE period for each participant with worsening from baseline is presented.

Time frame:
On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis
ParticipantsSAR445088
pH: <=4.60
pH: >=81
SecondaryPlasma Concentrations of SAR445088 (BIVV020)

Plasma samples were collected at specified timepoints.

Time frame:
1-hour post-dose on Day 1, on Days 8, 15, 29, 43, at Weeks 12, 16, 24, 32, 40, 48, 56, 64, 72, 80 and EOS visit, up to 103 weeks
Reported as:
Mean · microgram/milliliter (mcg/mL)
Plasma Concentrations of SAR445088 (BIVV020)
microgram/milliliter (mcg/mL)SAR445088
Day 1: 1-hour post-dose1186.00 ± 254.24
Day 8668.09 ± 139.19
Day 15657.64 ± 107.33
Day 29631.80 ± 64.52
Day 43627.56 ± 84.39
Week 12736.78 ± 164.07
Week 16786.00 ± NA
Week 24781.63 ± 276.73
Week 32695.67 ± 343.75
Week 40602.33 ± 385.64
Week 48559.33 ± 300.73
Week 56602.80 ± 224.08
Week 64615.80 ± 247.91
Week 72584.25 ± 243.37
Week 80602.50 ± 287.79
EOS (Week 103)206.46 ± 157.42
SecondaryNumber of Responders to SAR445088 (BIVV020)

A participant was a responder if the platelet count was \>=50 × 10\^9/L and there was a greater than 2-fold increase from baseline, measured on 2 occasions at least 7 days apart with the absence of bleeding \[bleeding score \>=2 on the World Health Organization (WHO) bleeding scale\] while the platelet counts were maintained above the threshold and lack of combination ITP therapy during this period. WHO bleeding scores: 1=Petechiae; 2=Mild blood loss; 3=Gross blood loss; and 4=Debilitating blood loss.

Time frame:
At Weeks 24 and 56
Reported as:
Count of participants · Participants
Number of Responders to SAR445088 (BIVV020)
ParticipantsSAR445088
Week 242
Week 562
SecondaryTime to First Platelet Response

Time to first platelet response was defined as greater than or equal to each of the following values: 50 × 10\^9/L or 100 × 10\^9/L (confirmed by 2 measurements at least 7 days apart). It was calculated as date of first occurrence of confirmed platelet count response before rescue therapy.

Time frame:
From Baseline (Day 1) up to Week 56
Reported as:
Median · weeks
Time to First Platelet Response
weeksSAR445088
Platelet count>=50 x 10^9/L18.5 (13.5 to 49.5)
Platelet count>=100 x 10^9/L18.5 (13.5 to 49.5)
SecondaryPercentage of Participants Who Did Not Require Rescue Therapy for an Acute Episode of Thrombocytopenia After Week 3

Data was collected to assess the effect of treatment with SAR445088 (BIVV020) on the requirement for rescue ITP therapy.

Time frame:
Up to Week 84
Reported as:
Number · percentage of participants
Percentage of Participants Who Did Not Require Rescue Therapy for an Acute Episode of Thrombocytopenia After Week 3
percentage of participantsSAR445088
Week 3 to Week 24 during treatment period75.0
Week 3 to Week 56 during treatment period75.0
Week 3 to the end of on-treatment period75.0
SecondaryNumber of Participants With Anti-Drug Antibody (ADAs) Response to SAR445088 (BIVV020)

Plasma samples were analyzed for the presence of ADAs for SAR445088 (BIVV020) using validated assays. Treatment-induced ADA was defined as ADAs that developed during the treatment-emergent period and without pre-existing ADA. Pre-existing ADA was defined as ADAs present in samples drawn before first study treatment administration. Treatment-boosted ADA positive was defined as pre-existing ADA (i.e., ADA positive at baseline) that was boosted at least a 9-fold increase of titer values during the treatment-emergent period than the baseline. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive during the treatment-emergent period. Inconclusive ADA was defined as the one that could not irrefutably be classified as with or without treatment-emergent ADA.

Time frame:
Up to Week 103
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADAs) Response to SAR445088 (BIVV020)
ParticipantsSAR445088
Participants with ADA negative or missing at baseline11
Participants with treatment-induced ADA0
Participants with pre-existing ADA1
Participants with treatment-boosted ADA0
Participants with treatment-emergent ADA during 24-week treatment period0
Participants with treatment-emergent ADA during 52-week treatment period0
Participants without treatment-emergent ADA12
Participants with inconclusive ADA0

Adverse events

Collected over The TEAEs were collected from first study treatment administration (Day 1) up to Week 103. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAR4450880/12 (0%)2/12 (16.7%)8/12 (66.7%)
Most frequent serious events
Most frequent serious events
EventSAR445088
AppendicitisInfections and infestations1/12
Cerebrovascular AccidentNervous system disorders1/12
Abdominal Pain UpperGastrointestinal disorders1/12
Most frequent other events
Showing 10 of 32
Most frequent other events
EventSAR445088
Covid-19Infections and infestations3/12
FatigueGeneral disorders3/12
DiarrhoeaGastrointestinal disorders2/12
InfluenzaInfections and infestations1/12
Post-Acute Covid-19 SyndromeInfections and infestations1/12
SinusitisInfections and infestations1/12
LymphadenopathyBlood and lymphatic system disorders1/12
Decreased AppetiteMetabolism and nutrition disorders1/12
HyperglycaemiaMetabolism and nutrition disorders1/12
AphasiaNervous system disorders1/12

Baseline characteristics

Enrolled population consisted of all participants from screened population who had been allocated to a treatment regardless of whether the treatment was received or not.

Age, Continuous
Age, Continuous(years)SAR445088
Mean54.7 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)SAR445088
Female4
Male8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SAR445088
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White7
More than one race0
Unknown or Not Reported2
08

Study locations

9 sites
  • Investigational Site Number :8400001
    Washington D.C., District of Columbia 20007, United States
  • Investigational Site Number :8400002
    Tamarac, Florida 33321, United States
  • Investigational Site Number :2030002
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number :2760001
    Essen, 45147, Germany
  • Investigational Site Number :5280001
    Leiden, 2333 ZA, Netherlands
  • Investigational Site Number :7240002
    A Coruña, A Coruña [La Coruña] 15006, Spain
  • Investigational Site Number :7240001
    Palma de Mallorca, 07120, Spain
  • Investigational Site Number :7240003
    Seville, 41013, Spain
  • Investigational Site Number :8260002
    London, London, City of W12 0HS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Feb 2022, 12 months.

Results were first posted in Feb 2024, 2 years after primary completion. A results delay was requested in Feb 2023.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2020
First posted
Dec 17, 2020
StartActual
Feb 4, 2021
Primary completionActual
Feb 15, 2022
CompletionActual
Feb 7, 2023
Results delay requested
Feb 13, 2023
Results first posted
Feb 22, 2024
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04669600
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Feb 4, 2021
Primary completion
Feb 15, 2022
Completion
Feb 7, 2023
Results posted
Feb 22, 2024
Last update
Sep 10, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riliprubart

Start the discussion